New Zealand Brain Research Institute recruiting for phase 2, page-6

Yes, when you start late, extend the treatment time to 1y and apply IND in the USA as late as 2H this year, the results are not ready earlier. So "the transformative year 2022" is not based on ph2 results. Stamler thinks perhaps that when the 60 patients have been recruited, perhaps all of them this year, 2022 can be called "transformative". I think that there needs to be something else and not only bioMUSE results.

The primate study (PD) could give us interesting results and with good safety reports from the phase 2 study, a human PD study, phase 3, could be in planning, while waiting these 2 long years.

With PBT2 it is much quicker to do the needed human studies but in PD a long treatment is needed. Maybe Stamler is not reporting anything of PBT2 progression.